Drug development is often described as a failure-prone industry. Our goal is to reduce toxicity-related attrition through science-based risk management.
-
Support strategic Go/No-Go decisions through risk-benefit analysis at the nonclinical stage
-
Resolve toxicity issues affecting drug candidates in development
-
Advance nonclinical development through improved toxicology testing methods and technology transfer
-
Develop and disseminate interpretation algorithms that enable industry-led attrition management
-
Develop skilled professionals through continuing education